Citations

Clear

1056 citation(s) found for "Sharma, D".

Abstract WP146: White Matter Disease and Recurrent Stroke in ESUS: A Propensity-Weighted Analysis from the CASPR Registry
Khasiyev, Farid, Borghei, Alireza, D'Souza, Marissa, Kerrigan, Deborah, Eklund, Kelsey , Yaghi, Shadi, Melkumova, Emiliya , Glover, Patrick , Nahab, Fadi, Shahrivari, Mahan, Nedelcu, Simona , Liebeskind, D, Rothstein, Aaron, Zha, Alicia , Kasab, Sami Al, Farooqui, Mudassir, Rojas-Soto, Diana , Aziz, Yasmin, Herpich, Franziska , Nguyen, Thanh N., Kam, Wayneho , Dumitrascu, Oana, Alvi, Muhammad , Krishnaiah, Balaji , Omran, Setareh Salehi , Linares, Guillermo , Coevering, Russell J. Van , Penckofer, Mary, Thon, Jesse, Mannion, Shani, Havenon, Adam de, Sharma, Richa, Smith, Matthew , D’Souza, Marissa , Lineback, Christina , Kerrigan, Deborah , Yaghi, Shadi , Culbertson, Collin J , Jillella, Dinesh , Nour, Hassan Aboul , Rothstein, Aaron , Kasab, Sami Al , Farooqui, Mudassir , Aziz, Yasmin , Nguyen, Thanh N. , Brorson, James R. , Penckofer, Mary , Thon, Jesse , Peter, Shani , Sharma, Richa , Siegler, James E.

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp146 Get It

Background: Embolic stroke of undetermined source (ESUS) comprises infarct mechanisms presumed to be embolic and non-lacunar. One explanation for the lack of superiority of anticoagulation over aspirin is the inclusion of subcortical infarcts with white matter disease (WMD), reflecting small vessel pathology. We hypothesized that WMD is associated with recurrent ischemic stroke (RIS) in ESUS and this risk is not lessened by anticoagulation. Methods: We conducted a secondary analysis of the multicenter Cardiac Abnormalities in Stroke Prevention and Recurrence (CASPR) registry, including ESUS patients from 27 U.S. centers (2015–2024). WMD severity was graded using the Fazekas scale from MRI and dichotomized as mild (0–1) vs. moderate-to-severe (2–3). The primary outcome was RIS. Secondary outcomes were major bleeding and all-cause mortality. Inverse probability of treatment weighting (IPTW) adjusted for baseline differences. Cox proportional hazards models assessed associations between WMD and outcomes. Subgroup analyses explored effect modification by age, risk factors, and treatment type. Results: Among 1,890 ESUS patients with MRI data, 684 (36.2%) had Fazekas 2–3. These patients were older with more vascular risk factors, but IPTW achieved covariate balance. In the weighted cohort, RIS occurred more frequently in Fazekas 2–3 vs. 0–1 (7.1% vs. 4.6%/year; HR 1.56, 95% CI 1.10–2.22, p = 0.01). Major bleeding and mortality were similar (bleeding: 1.7% vs. 1.8%/yr, HR 0.96, p = 0.92; death: 7.0% vs. 6.7%/yr, HR 1.04, p = 0.81). Subgroup analyses showed no interaction between WMD and age, vascular risk factors, or treatment type (antiplatelet vs. anticoagulation), suggesting consistent RIS risk in those with higher WMD. Discussion: Moderate-to-severe WMD identifies ESUS patients at higher risk of ischemic stroke recurrence, with no mitigation by anticoagulation. These findings suggest that WMD may indicate non-embolic mechanisms and support the use of imaging-based risk stratification in ESUS.
Abstract DP154: The Association Between Comprehensive Evaluation in ESUS and Stroke Recurrence: A secondary analysis of the Cardiac Abnormalities in Stroke Prevention and risk of Recurrence Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Eklund, Kelsey , Khasiyev, Farid, Kasab, Sami Al, D'Souza, Marissa, Kerrigan, Deborah , Sharma, Richa, Nour, Hassan Osama Mostafa Aboul, Nahab, Fadi, Omran, Setareh Salehi , Linares, Guillermo , Sehgal, Siddharth, Singh, Eesha , Zha, Alicia , Mannion, Shani, Chen, Lucia , Thompson, Sean, Thon, Jesse, Penckofer, Mary , Yu, Wenzheng, Qdais, Ahmad Abu, Dumitrascu, Oana, Talat, Fawad , Kang, Jieun, Aziz, Yasmin, Zubair, Adeel , Havenon, Adam de, Bowman, Anna , Shahrivari, Mahan, Liebeskind, D, Nedelcu, Simona , Ali, Hamid , Kam, Wayneho , Nguyen, Thanh N., Herpich, Franziska , Farooqui, Mudassir, Rojas-Soto, Diana , Yaghi, Shadi, Khan, Fahad , Stretz, Christoph , Siegler, James E. , Lineback, Christina , Kasab, Sami Al , Culbertson, Collin J , D’Souza, Marissa , Stamm, Brian , Ro, Jennifer , Sharma, Richa , Nour, Hassan Aboul , Peter, Shani , Thon, Jesse , Jillella, Dinesh , Sloane, Kelly L , Aziz, Yasmin , Brorson, James R. , Farooqui, Mudassir

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp154 Get It

Background: Although the embolic stroke of undetermined source (ESUS) construct was proposed as a unifying concept for embolic-appearing strokes without an identified cause, it includes patients with diverse and often unrecognized underlying mechanisms. This study investigates the differential rate of recurrent stroke according to the completeness of neurodiagnostic testing in a diverse multicenter cohort. Methods: This was a retrospective analysis of a multicenter observational cohort study (n=27 sites). Patients with ESUS were categorized into three groups: (1) established mechanism after further work up (ESUS-E), (2) patients who underwent a comprehensive diagnostic workup without an identified etiology (ESUS 2.0), and (3) no advanced workup (ESUS-NAW). The primary outcome of recurrent ischemic stroke was assessed by comparing ESUS 2.0 to both ESUS-E and ESUS-NAW groups using adjusted Cox proportional hazards models. Results: Of the 2,281 patients included, 694 (30%) were classified as ESUS-E, 344 (15%) as ESUS 2.0, and 1,443 (55%) as ESUS-NAW. The ESUS 2.0 group had a significantly lower annualized recurrence rate (1.98 per 100 person-years) compared to both the ESUS-NAW group (7.7 per 100 person-years; aHR 0.27, 95% CI: 0.11–0.62; p=0.002) and the ESUS-E group (6.10 per 100 person-years; aHR = 0.35; 95% CI 0.15–0.85, p=0.020). Within the ESUS-E group, cancer (aHR 5.33; 95% CI: 2.09–13.63; p < 0.001) and non-stenosing atherosclerotic disease or arch atheroma (aHR 3.40; 95% CI: 1.18–9.83; p = 0.023) were associated with significantly increased risk of recurrence when compared to ESUS 2.0. Conclusion: These findings demonstrate a lower risk of recurrent stroke in patients classified as ESUS 2.0, diverging from the 5–6% annual recurrence rates observed in prior ESUS trials. These findings suggest that patients who receive comprehensive diagnostic evaluation without identification of a specific etiology have a lower risk of recurrent stroke, an important consideration for the design of future ESUS studies.
Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury
Harris, Zachary M , Korde, Asawari, Manning, Edward P., Stanley, Gail, Shin, Yosep, Mitchell, Kennedy, Schulenburg, Alexa von der, Sun, Ying, Hu, Buqu , Shin, Hyeon Jun , Joerns, John, Clark, Brian, Placek, Lindsey , Moldobaeva, Aigul, Sharma, Lokesh , Sauler, Maor, Rajagopalan, Govindarajan, Zhang, Xuchen, Wang, He, Ghaedi, Mahboobe, Koff, Jonathan L, Zhang, Xuchen , Manning, Edward P , Korde, Asawari , Khoury, Johad , Sun, Ying S., Joerns, John , Clark, Brian J., Unutmaz, Derya , Sauler, Maor , Ghaedi, Mahboobe , Kang, Min‐Jong , Koff, Jonathan L.

Mayo Clinic

BMJ Open Respiratory Research | January 27, 2026 | Volume: 13 | Issue: 1 | Pages: e003323

10.1136/bmjresp-2025-003323 | PMID 41592865 Get It

Background While delivery of supplemental oxygen is a life-saving therapy, exposure to high oxygen, called hyperoxia, leads to increased intensive care unit mortality. Hyperoxia induces oxidant-mediated acute lung injury (ALI) and pulmonary cell death, called hyperoxic ALI (HALI). Elucidating molecular mechanisms in HALI could identify therapeutic targets in ALI. Methods In the current study, we examined in vivo effects of HALI on Beclin-1 (BCN1), which regulates autophagy, and modulation of BCN1 by epidermal growth factor receptor (EGFR). Effects of HALI on BCN1 and autophagy were examined in mice with genetically decreased EGFR (EGFR Wa5/+ ). Wildtype (WT) and EGFR Wa5/+ mice were exposed to 100% oxygen for 24–72 hours along with normoxia controls (eight groups; n=4–6/group), and analysis of pulmonary BCN1 and autophagy was completed. Results In WT, HALI led to increased BCN1 (59% increased total BCN1/β-Actin; p<0.01) in lung and alveolar epithelium (484% increased H-score; p<0.001). HALI led to decreased microtubule-associated protein 1B-light chain (LC3B)-II/-I ratios (43% decrease; p<0.05) and increased p62 (93% increase; p<0.05), suggesting reduced autophagic flux. In human alveolar type-II cells derived from induced pluripotent stem cells (AT2s iPSC ), HALI caused increased LDH release (130% increase; p<0.0001) and decreased LC3B-II/-I ratios (32% decrease; p<0.05). We previously showed that EGFR Wa5/+ mice are protected in HALI. In the current study, EGFR Wa5/+ mice showed increased pulmonary BCN1 (122% increase; p<0.05), reduced phosphorylated-(p-)/total BCN1 (47% decrease; p<0.05) and decreased LC3B-II/-I ratios (70% decrease; p<0.01) in HALI compared with WT. In addition, wortmannin (1 mg/kg), which decreases BCN1-mediated autophagy, increased mortality in HALI compared with vehicle control (n=10/group; 18% decreased hours survived; p<0.001). Conclusions These data delineate a novel cell death pathway in HALI involving BCN1 and EGFR with therapeutic potential.
Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology
Eijsvogels, Thijs M H , Kim, Jonathan H. , Aengevaeren, Vincent L. , D’Ascenzi, Flavio , Churchill, Tim, Dineen, Elizabeth H. , Garza, M Sanz-De La, Gati, Sabiha , Hálasz, Géza , Haugaa, Kristina H. , Heidbüchel, Hein , Lampert, Robin, Krishnan, Sheela , Maestrini, V, Martinez, Matthew, Phelan, Dermot , Thompson, Paul D. , Churchill, Timothy W. , Churchill, Timothy W , Sanz-de la Garza, María , Haugaa, Kristina , La Gerche, Andre , Lampert, Rachel , Krishnan, Sheela , Maestrini, Viviana , Papadakis, Michael , Perone, Francesco , Phelan, Dermot , Sharma, Sanjay , Thompson, Paul D , Baggish, Aaron L , Claessen, Guido , Eijsvogels, Thijs M.H. , Gerche, André La , Martinez, Matthew W. , Perone, Francesco , Baggish, Aaron L.

Mayo Clinic

European Heart Journal | January 16, 2026 | Volume: 47 | Issue: 21 | Pages: 2541-2560

10.1093/eurheartj/ehag040 | PMID 41947397 Get It

Abstract Exercise training improves cardiovascular health and reduces the risk for future cardiovascular events and mortality. However, emerging evidence suggests that Masters athletes may have a higher prevalence of cardiovascular abnormalities, such as atrial arrhythmias, coronary atherosclerosis, aortic dilatation, and myocardial fibrosis, compared to their less active peers. The clinical management of Masters athletes may be challenging as available guidelines for such conditions are generally based on data derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals. Other unique challenges in the clinical assessment of Masters athletes include differences in symptomatic presentations compared to sedentary individuals, potential resistance to the initiation of pharmacologic treatment, and the increasing availability of consumer wearable health data that may provide relevant information on their cardiovascular health status. The purpose of this joint EAPC/ESC and ACC Clinical Consensus Statement is to provide an in-depth update on the current state of knowledge on abnormal cardiovascular findings in Masters athletes. We present an expert-based approach on the diagnostic assessment, management, and prognosis of (i) atrial fibrillation, (ii) bradyarrhythmias, (iii) ventricular arrhythmias, (iv) coronary atherosclerosis, (v) aortic dilatation, (vi) myocardial fibrosis, and (vii) exercise-induced arrhythmogenic cardiomyopathy. Clinical challenges, areas of ongoing controversy, and uncertainty and the potential underlying mechanisms are discussed. We also present future perspectives and research directives to further refine current best practice strategies. This includes the need for clinical outcome studies, dedicated randomized controlled trials in athletes, and international registries with diverse populations and longitudinal follow-up to evaluate the natural history of cardiac abnormalities and facilitate development of evidence-based approaches in the clinical management of Masters athletes with cardiovascular abnormalities.
P-1554. Cytokine dysregulation in Scrub typhus: Correlation with complications and disease severity
Kumar, MS Mohan, Biswal, Prof Manisha, Sharma, Nalin , singh, Rojar, Prasad, Deba, Behera, Ashish, Singla, N, Sharma, Nalin , Biswal, Manisha , Pannu, Ashok Kumar , Behera, Ashish

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1734 Get It

Abstract Background Pathogenesis of Scrub typhus (ST), a tick-borne acute zoonotic disease caused by the bacterium Orientia tsutsugamushi, involves infection of vascular endothelial cells, triggering a potent cytokine host response that causes organ damage. Methods Prospective study in a tertiary care hospital in North-west India in 30 cases of Scrub typhus. Measurements of cytokines IL-17A, INF-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2 were carried out at admission in all 30 patients and a control group of 10 healthy persons using BDTM Cytometric Bead Array, BD Biosciences, San Diego, California, USA. Results Mean age of the entire cohort was 36 years, and the male-female ratio was 2:1. The most common symptoms were dyspnea 87%, altered sensorium 23%, abdominal pain 20%, decreased urine output 10% and myalgia in 10%. On clinical examination, eschar was present in 40%. Investigations revealed anemia in 80% cases, leukocytosis in 46.6%, thrombocytopenia in 90%, jaundice in 53.3% and elevated serum transaminase levels in 84% cases. Of all complications, acute respiratory distress syndrome occurred in 90% patients, acute kidney injury in 37% patients, acute meningoencephalitis syndrome in 30%, and myocarditis in 23%. The mean APACHE 2 score of the entire cohort was 12 . Multi-organ dysfunction syndrome (MODS) was seen in 67% of cases, and the overall mortality rate was 20%. On Fisher's Exact Correlation analysis, presentation with meningoencephalitis, myocarditis, systemic acidosis, and a high APACHE 2 score correlated with mortality. The serum levels of cytokines were elevated in all patients compared to the healthy control group (Table 1), but did not significantly differ between survivors and non-survivors. Furthermore, the elevated levels of TNF-α (p=0.004) and IL-10 (p=0.029) strongly correlated with multi-organ dysfunction syndrome (MODS). Conclusion In Scrub Typhus, the strong correlation of serum levels of TNF-α and IL-10 with multi-organ dysfunction syndrome (MODS) suggests their involvement in disease progression. The high prevalence of acute respiratory distress syndrome and MODS, alongside a mortality rate of 20%, highlights the critical nature of scrub typhus and the necessity for early recognition of complicated disease and intervention. Disclosures All Authors: No reported disclosures
Impact of Age and Sex on Extra‐Brain, Off‐Target Binding in Tau PET Scans (18F‐FTP)
Ghatamaneni, Sujala, Kim, Daneil, Nycklemoe, Marin, Choi, Yurim Claire , Apgar, Christopher, Kandimalla, Mahathi , Jacobson, David N, Kung, Tiffany, Sharma, Vamika, Hol, Haakon R. , Albertson, Sabrina M., Schwarz, Christopher G, Gunter, Jeffrey L. , Petersen, Ronald, Jack, Clifford R., Lowe, VJ, Ghatamaneni, Sujala, Apgar, Christopher J., Kung, Tiffany, Lim, Seokbeen , Lundt, Emily S. , Schwarz, Christopher G. , Petersen, Ronald, Jack, Clifford R. , Min, Hoon-Ki Paul

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107719 Get It

Abstract Background The tau PET imaging with 18F‐flortacipir (18F‐FTP) has focused interest in accurately tracking longitudinal tau changes in Alzheimer's disease [1]. Thus, minimizing variability is critical. Off‐target signal has the potential to complicate interpretation of tau‐PET imaging due to potential spillover or bleed‐in effects, with increased effects seen in later stages of Alzheimer's due to cerebral atrophy and proximity of off‐target areas to relevant cortical areas[2]. Previously, we demonstrated the effect of uptake period activity on 18F‐FTP signal. With increasing recent interest in demographic factors that may affect off‐target binding, we investigated the effect of age in extra‐cerebral off‐target signal in 18F‐FTP PET imaging. Method Standard 18F‐FTP PET protocol was performed in 330 participants. Two independent readers measured tau uptake in predetermined off‐target regions, including extraocular muscle, meninges, and occipital bone among others. Linear regression models assessed the relationship between participants’ age, sex, and tau uptake values (SUV and SUVr) (SUV = (Tissue radioactivity concentration / Injected dose) / Body weight & SUVr = SUV of target region/ SUV of reference region.) Result Sex had a significant effect on off‐target signal in most brain regions, with variable positive or negative correlation based on area. Notably, SUV in the eyeball‐retina, occipital bone, upper skull meninges all showed significant positive correlation with sex, with ‘male’ status generally associated with lower SUV. The greatest effect of sex was observed in superior skull meninges, occipital bone, and internal carotid artery ( p <0.001). Age showed minimally affected SUV and SUVr in off‐target regions. SUVr values show a significant correlation with SUV values of upper skull meninges in sex. Cognitive status did not significantly affect off‐target SUV. Conclusion We observed that sex significantly affected extra‐brain off‐target signal in 18F‐FTP PET imaging, while age has minimal effect, adding to previous evidence of off‐target binding within brain regions. Further evaluation is necessary to understand the age‐related effects on off‐target regions. As a result, the variability introduced by sex may pose challenges to studying tau accumulation.
Study Protocol for a Single-Arm Pilot Feasibility Trial Evaluating a Structured Breathing-Based Intervention to Reduce Burnout and Enhance Mental Well-Being Among Healthcare Professionals in Community-Based Practice Settings
Sharma, Pravesh , Osman, Rowa, Nycklemoe, Marin, Boos, Danielle M., Murph, Crystal M., Flock, Carolyn, Jacobson, David , Lim, Seokbeen , Nation, Jody L., Wilson, Melissa A. , Schüldt, K, Min, Paul H., Sharma, Pravesh , Nycklemoe, Marin, Flock, Carolyn R., Jacobson, David N., Schuldt, Kristina

Mayo Clinic

No container title available | January 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.07.26343607 Get It

Abstract Introduction Burnout among healthcare professionals remains a critical public health issue linked to impaired cognition, emotional exhaustion, and diminished clinical performance. Structured breathing practices have demonstrated promise in improving autonomic regulation and cerebral oxygenation, yet their feasibility and acceptability in real-world healthcare settings remain underexplored. Objectives This single-arm pilot feasibility trial aims to evaluate the feasibility, acceptability, and implementation appropriateness of a structured breathing-based intervention for healthcare professionals across community-based Mayo Clinic Health System (MCHS) sites. Secondary objectives include assessing usability and engagement with the mobile breathing platform, while exploratory analyses will examine preliminary signals of change in psychological well-being and cerebral hemodynamics. Methods and Analysis A total of 40 physicians and nurses reporting moderate or greater burnout will be enrolled across four MCHS sites. Participants will complete a four-month structured breathing program delivered primarily online, supported by a mobile application for practice tracking. Assessments will occur at baseline, 2 months, and 4 months, with optional functional near-infrared spectroscopy (fNIRS) measures of cerebral oxygenation collected at baseline and 4 months in a subset. Primary outcomes include (1) recruitment yield, retention, and adherence rates; (2) acceptability and participant satisfaction (survey and qualitative feedback); and (3) implementation appropriateness measured by the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). Secondary outcomes assess digital engagement and usability through mobile analytics and the System Usability Scale (SUS). Exploratory outcomes evaluate psychological indicators—burnout, depression, anxiety, perceived stress, sleep, fatigue, professional fulfillment, and resilience—and physiological endpoints (fNIRS). Analyses will be descriptive, summarizing feasibility metrics with 95% confidence intervals. Progression criteria (recruitment ≥75%, retention ≥80%, adherence ≥70%, AIM/IAM/FIM ≥4.0) will determine readiness for a definitive hybrid effectiveness–implementation trial. Ethics and Dissemination The study is approved by the Mayo Clinic Institutional Review Board (IRB # 25-009320). All participants will provide informed consent. Study procedures ensure confidentiality, cultural sensitivity, and participant safety. Data will be securely stored in REDCap and disseminated through peer-reviewed publications and scientific conference ClinicalTrials.gov ID The study has been prospectively registered at ClinicalTrials.gov (Identifier NCT07218458 ). Strengths and Limitations Evaluates a structured breathing-based intervention using both subjective and objective indicators of feasibility, including recruitment, retention, adherence, and implementation appropriateness. Integrates mobile application analytics with standardized implementation measures (AIM, IAM, FIM) to capture digital engagement and real-world usability. Incorporates functional near-infrared spectroscopy (fNIRS) to explore physiological mechanisms underlying burnout recovery, linking cerebral oxygenation to behavioral outcomes. Conducted across diverse community-based Mayo Clinic Health System sites, enhancing ecological validity and relevance to decentralized clinical settings. Limitations include the single-arm, region-restricted design, modest sample size, and reliance on volunteer participants, which constrain generalizability and preclude causal inference; exploratory outcomes are intended to guide future trial refinement.
The Renal Micro-RNA Expression Profile of Pkd1 RC/RC Mice Changes Longitudinally with the Progression of the Disease
Sharma, Nalin , Zheng, Jamie , Alsawaf, Yahya , Singha, Santu K., Xu, Xiaohong , Zhang, Youwen, Vučković, Ivan , Macura, Slobodan , Hanna, Christian , Hogan, Marie C. , Eirin, Alfonso, Sharma, Nalin , Eirin, Alfonso , Irazabal, Maria V , Macura, Slobodan I , Hanna, Christian , Vuckovic, Ivan , Alsawaf, Yahya , Hogan, Marie C , Eirin, Alfonso , Irazabal, María V.

Mayo Clinic

Kidney360 | January 2, 2026 | Volume: 7 | Issue: 6 | Pages: 1212-1226

10.34067/kid.0000001108 | PMID 41481368 Get It

Key Points Experimental autosomal dominant polycystic kidney disease is associated with longitudinal changes in the kidney micro-RNA and mRNA profiles. Alterations in cellular transport, a feature of CKD, and a common biological process within polycystic kidney disease models and human autosomal dominant polycystic kidney disease, is present from early stages. Early versus late micro-RNA expression changes in autosomal dominant polycystic kidney disease could be targeted for a more tailored therapeutic intervention in the disease. Background Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive development and enlargement of bilateral kidney cysts, which often leads to kidney failure. This study comprehensively characterized the expression profile of micro-RNAs (miRNAs) and their target genes in Pkd1 RC/RC mice and further compared them with other murine models of polycystic kidney disease (PKD) and a model of CKD and individuals with ADPKD. Methods Pkd1 RC/RC and wild-type (WT) mice ( n =10 each, five males and five females) were studied at 1, 6, and 12 months. At each time point, kidney volume was determined in vivo (magnetic resonance imaging), followed by ex vivo histomorphometric analyses. In randomly selected Pkd1 RC/RC and WT mouse kidneys ( n =5/genotype, at 1 and 12 months), miRNA-sequencing (seq) was performed, followed by mRNA-seq, integrated (miRNA-seq/mRNA-seq analysis), and functional analysis of miRNA target genes. Venn diagrams were constructed to identify overlapping and novel differentially expressed (DE) miRNAs in Pkd1 RC/RC and other commonly used murine models of PKD, diabetic kidney disease, and individuals with ADPKD. Results miRNA-seq analysis identified 41 and 181 miRNAs DE in Pkd1 RC/RC versus WT kidneys at 1 and 12 months, respectively, which were confirmed by quantitative PCR. Target genes of miRNAs DE in Pkd1 RC/RC at early stages encoded for proteins mainly implicated in cell proliferation and α -ketoglutarate ( α -KG) transport, whereas those DE at late stages encoded for transport proteins involved in proinflammatory and metabolic processes. Urine α -KG concentration ( 1 H nuclear magnetic resonance spectroscopy), its fractional excretion, and tissue levels were higher in Pkd1 RC/RC during the entire course of the disease and associated with decreased protein expression of α -KG transporters sodium-coupled dicarboxylate transporter 3 and organic anion transporter 1. We further identified common DE miRNAs among murine models of PKD, diabetic kidney disease, and previous reports in individuals with ADPKD, as well as several novel miRNAs DE in early and late Pkd1 RC/RC kidneys, which have not been previously reported in either other murine models of PKD or patients with ADPKD. Conclusions Our study demonstrates that the renal miRNA expression profile changes longitudinally with the progression of the disease and might suggest that the post-transcriptional regulation of α -KG transport could represent a novel early feature of the disease.
Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study
Chacko, Shireen R, Sharma, Shubhangi Sharma , Ahmadian, Sarina , Saini, JS, Fell, Vanessa , Peersen, Anina, Atkinson, Elizabeth J, Gruber, Lucinda , Gompel, Jamie J. Van , Simha, Vinaya , Young, William F, Bancos, Irina, Chacko, Shireen R , Peersen, Anina F, Van Gompel, Jamie J , Bancos, Irina , Chacko, Shireen R , Saini, Jasmine , Atkinson, Elizabeth J. , Young, William F., Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 25, 2025 | Volume: 111 | Issue: 6 | Pages: 1613-1627

10.1210/clinem/dgaf693 | PMID 41466357 Get It

Abstract Context Evidence on the evolution of cardiometabolic comorbidities following surgical remission of hypercortisolism is scarce. Objective To determine the impact of surgical remission on cardiometabolic comorbidities in patients with endogenous hypercortisolism and to identify factors associated with cardiometabolic improvement. Methods Prospective single-center cohort study (2019-2025) of adults with Cushing syndrome (CS) or mild autonomous cortisol secretion (MACS) with surgical remission of hypercortisolism. Outcomes included (1) changes in severity of hypertension, diabetes mellitus (DM), hyperlipidemia, and obesity between baseline, 3, and 12 months postremission and (2) factors associated with improvement in comorbidities. Results Among 357 patients (49% MACS, 36% pituitary CS, 10% adrenal CS, 5% ectopic CS; median age 53 years [interquartile range 42-62]; 81% women), 336 (94%) had hypertension, 241 (68%) had obesity, and 122 (35%) had DM. At a median of 12 months postsurgery, improvement in hypertension occurred in 70% (90/128) of patients with CS and 51% (60/117) of patients with MACS, DM in 90% (46/51) patients with CS and 37% (13/35) patients with MACS, and obesity in 79% (77/97) patients with CS and 20% (14/71) patients with MACS. In a multivariable analysis, higher baseline biochemical severity scores were associated with improvement in hypertension [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.1-1.5), DM (OR 2.5, 95% CI 1.7-4.1), and obesity (OR 1.5, 95% CI 1.2-1.8) at a median of 12 months postremission of hypercortisolism. Conclusion Postsurgical improvement of cardiometabolic comorbidities was observed in both patients with CS and MACS. Higher baseline biochemical severity scores were associated with higher postremission improvement in comorbidities.
Ferritin H Knockout Induces Differential Immunomodulatory Drug Responses in Multiple Myeloma Cell Lines
Sharma, Aarti , Pathangey, Latha , Chirackal, Sinto Sebastian, Shim, Kevin G. , Fonseca, Rafael Salvador Santos , Swaminathan, Sundararaman , Shim, Kevin G , Fonseca, Rafael

Mayo Clinic

European Journal of Haematology | December 22, 2025 | Volume: 116 | Issue: 4 | Pages: 391-401

10.1111/ejh.70084 | PMID 41423250 Get It

ABSTRACT Background Immunomodulatory agents (IMiDs) are a cornerstone in the successful management of multiple myeloma (MM). However, acquired IMiD resistance leading to disease relapses remains a major barrier. Hydrogen peroxide generation and oxidative stress are key mediators that determine IMiD's effectiveness in MM. Iron plays a key role in the generation of oxidative stress; therefore, cellular iron levels are tightly governed. FTH1 is the major iron storage protein that tightly regulates cellular iron availability. Hence, the present study is targeted to investigate the role of FTH1 in MM and IMiD resistance. Methods IMiD‐sensitive and IMiD‐resistant MM cells were analyzed for expression of iron‐metabolism genes. CRISPR‐cas9‐mediated knockout of FTH1 was performed and the after‐effects were assessed through multiple experiments. Results Initial analysis showed a positive correlation between FTH1 expression and IMiD resistance in MM cells. FTH1 ‐KO reduced IMiD sensitivity in the KMS11 cell line but had no effect on the RPMI8226 cell line. RNA‐seq data showed downregulation of ER‐stress and calcium signaling genes after FTH1 ‐KO. Further, KMS11‐ FTH1 KO cells exhibited lower intracellular ROS, labile‐iron, and mitochondrial superoxide levels along with increased CD63, suggesting activation of L‐ferritin secretory pathways. Conclusion Data reveals a link between FTH1 , labile iron, ROS, and IMiD resistance in MM cells.